Located in Warsaw, Poland, this 14000 square meter facility comes with 2200 square meters of built-up production area and another 1000 square meters of warehouse capacity. Catering to key global markets with our portfolio, we are also a preferred CMO partner for supplying injectable medications locally in Europe. This EU GMP approved facility houses four production lines consisting of an ampoule line, a pre-filled syringe line, a high-speed liquid and a separate vial line with both liquid and lyophilization capabilities.

Steriscience acquired a majority stake in Brooks in 2021 gaining access to a dedicated Carbapenems facility located in Gujarat, India. Set up in the year 2015, the facility today has a 150 strong workforce and is situated on an area covering 66000 square meters with 11000 square meters of built-up areas covering production, quality control laboratories, warehouse, and administration blocks. Already catering to patients in key emerging markets including India, we received our first ANDA approval from this facility August 2022, and will be launching first set of products in the US and Europe markets.

Our supply chain for anti-infectives is further strengthened with recent investments in a greenfield API manufacturing unit at this facility, making Steriscience one of the few fully integrated players for Carbapenems globally, while ensuring cost competitiveness.